RNU6-1196P

Across TCGA pan-cancer cohorts, RNU6-1196P RNA is linked to patient survival in 9 of 34 cancer types, making it the most broadly survival-associated RNU6-1196P data layer.

The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where higher RNU6-1196P RNA is associated with worse disease-free survival. In most high-consensus cancer types, elevated RNU6-1196P expression acts as an unfavorable survival marker, although some lineages such as LAML and LUAD show a favorable association.

LIHC, PAAD, and KIRC are the cancer types where RNU6-1196P RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LIHC	DFS	Tertile	All	0.086	0.535	<.001	81	view →
PAAD	OS	Tertile	All	0.202	0.481	.003	45	view →
KIRC	OS	Tertile	All	0.505	0.649	.025	24	view →
LAML	DFS	Quartile	All	0.662	0.301	.011	18	view →
LUAD	DFS	Tertile	IV	1.000	0.285	.043	12	view →
SKCM	OS	Tertile	IV	0.415	0.861	.014	9	view →
LGG	DFS	Tertile	All	0.939	0.729	.022	6	view →
LUSC	OS	Tertile	All	0.845	0.743	.049	3	view →
KIRP	DFS	Tertile	All	0.236	0.626	.007	3	view →

Pink = unfavorable, green = favorable. Showing the 9 strongest of 9 lineages.

RNU6-1196P–LIHC (DFS)

Open the LIHC breakdown →